bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.06.05.730356

Spatial Compartmentalization of TCR Repertoires Between Primary Melanomas and Sentinel Lymph Nodes Reveals Distinct Clonal Architectures and Shared Antigen Recognition

Abstract

Primary tumors and their sentinel lymph nodes are functionally linked sites of anti-tumor immunity, yet how T cell receptor (TCR) repertoires are organized across these compartments remains incompletely understood. We thus performed TCR{beta} sequencing on paired primary melanoma tumors and sentinel lymph nodes from 24 treatment-naive patients to quantify TCR repertoire diversity and clonal architecture as markers of antigen-driven selection. Primary tumors exhibited markedly reduced TCR diversity and pronounced clonal dominance compared with matched lymph nodes, consistent with selective expansion of tumor-reactive T cells. Tumor-associated clonotypes displayed significantly longer CDR3 sequences driven by increased non-templated nucleotide insertions, a feature associated with neoantigen recognition, and showed biased TRBV and TRBJ gene usage indicative of CD8+ T cell enrichment. Annotation against known melanoma differentiation and cancer testis antigens identified only a small fraction of clonotypes with characterized specificities, and fewer than 10% of these were shared between tumors and lymph nodes, suggesting that most expanded tumor clonotypes recognize patient-specific antigens. To identify shared immune features beyond individual clonotypes, we applied ClustIRR to build a joint graph linking clonotypes across repertoires by CDR3 sequence similarity and detected Communities on the Joint graph (CJs) to uncover recurrent TCR sequence motifs. Differential occupancy analysis identified distinct CJs segregating tumors and lymph nodes, including a limited number of recurrent CJs targeting MART-1 epitopes, while the majority were patient-specific. Together, these data define spatially structured TCR repertoire architectures in human melanoma and establish a scalable framework for interrogating tumor-immune interactions. eLife DigestMelanoma is a skin cancer harboring many UV-associated mutations, making it recognizable to the immune system. T cells attack cancer using specialized molecular structures called T cell receptors (TCRs). They are frequently referred to as specific keys that only fit into the respective locks, i.e. HLA molecules presenting the target antigen. Surgeons often remove both the tumor and the tumor draining lymph node (aka sentinel lymph node). The tumor is where T cells directly fight cancer, while the sentinel lymph node is where new anti-tumor T cells are first activated. How these two sites coordinate immune surveillance is not completely understood. Here, Kitanovski and colleagues sequenced TCRs from paired tumors and sentinel lymph nodes obtained from melanoma patients. These analyses demonstrated that primary tumors have dramatically reduced TCR diversity, dominated by a few massively expanded T cell clones, whereas sentinel lymph nodes contain broad, balanced repertoires. This reveals intense local selection within the tumor-a small set of tumor-specific T cells expand repeatedly while the lymph node preserves diverse immune reserves. Examining TCR structure revealed a second key difference. Tumor-infiltrating T cells possess on average slightly longer CDR3 loops-the region contacting antigens-especially among dominant clones. These longer loops arise from random nucleotide insertions. Prior work shows that self-antigen-specific T cells have shorter CDR3s due to thymic constraints, whereas T cells recognizing tumor-specific mutation-derived neoantigens escape these restrictions and have longer CDR3s. Thus, tumor TCRs appear tailored for recognizing patient-specific neoantigens. The authors could only use TCRs matching known databases for shared melanoma antigens like MART-1 to identify TCR-specific epitopes; most tumor-expanded TCRs could not be annotated because patient-specific neoantigens are not in public databases. This limitation itself is informative- most expanded tumor TCRs likely target private neoantigens. Grouping TCRs by sequence similarity into "communities" revealed striking patterns: sentinel lymph nodes showed conserved community composition across patients, consistent with responses to common viruses, while tumor repertoires were highly individualized, reflecting each tumors unique mutations. These findings establish how anti-melanoma immunity is spatially organized: sentinel lymph nodes contain diverse T cell landscapes, while in primary tumors melanoma-infiltrating T cells appear to have undergone intense selection for neoantigen recognition. This provides a foundation for using TCR features as biomarkers and designing personalized T cell therapies.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kitanovski, S., Srinivas, N., Schrama, D., Hoffmann, D., Becker, J.. 2026-06-09. Spatial Compartmentalization of TCR Repertoires Between Primary Melanomas and Sentinel Lymph Nodes Reveals Distinct Clonal Architectures and Shared Antigen Recognition. https://doi.org/10.64898/2026.06.05.730356

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

MYC-Hyperactivated Osteosarcoma Models Exhibit Resistance to Cabozantinib plus TIGIT Blockade

Background: Relapsed and refractory osteosarcoma (OS) remains a major therapeutic challenge, with fewer than 20% of patients surviving beyond 3 years. Increasing evidence indicates that MYC amplification/overexpression is associated with inferior survival. Small molecule inhibitors and immunotherapies have limited single-agent efficacy in pediatric solid tumors. Using syngeneic cell lines derived from p53-driven and MYC-hyperactivated genetically engineered mouse models (GEMMs) of OS, we tested cabozantinib, a multi-tyrosine kinase inhibitor with immunomodulatory properties, with TIGIT immune checkpoint blockade and investigated mechanisms underlying therapeutic response and resistance. Methods: In vitro cabozantinib sensitivity was established in GEMM-derived cell lines. Mice bearing tibial tumors were randomized to vehicle control, cabozantinib, anti-TIGIT antibody, or combination therapy, and tumor growth and survival assessed after a 3-week treatment period. Temporal RNA sequencing was performed at early (8-15 days) and late (18-24 days) time points to characterize transcriptomic changes associated with efficacy. Results: MYC-hyperactivated cell lines were more resistant to cabozantinib in vitro than p53-driven lines (mean IC50 5.51 vs 0.65 mciroM, p=0.0016). In p53-driven orthotopic models, combination therapy significantly decreased tumor growth and improved survival compared to solvent and cabozantinib alone, while in MYC-hyperactivated models cabozantinib-containing regimens delayed tumor progression relative to control or anti-TIGIT monotherapy, however the addition of anti-TIGIT did not significantly improve survival over cabozantinib alone. Temporal transcriptomics revealed upregulated anti-tumor immune-response pathways and decreased M2 macrophages only with combination treatment in the p53-driven model. In contrast, combination-treated MYC-hyperactivated models demonstrated increased TNF signaling and elevated Cxcl5 and Ccr2 expression, indicative of increased myeloid cell recruitment, and upregulation of extracellular matrix (ECM) remodeling pathways suggest a therapy-induced stress adapted state that propagates treatment resistance over time. Conclusion: New therapies are needed for patients with relapse or refractory OS. By targeting tumor-intrinsic resistance mechanisms and modulating the tumor microenvironment using cabozantinib and anti-TIGIT therapy, improved tumor control and survival was achieved in p53-driven orthotopic OS models. MYC-hyperactivated models were able to overcome therapeutic pressure and employ myeloid recruitment and ECM remodeling programs to achieve treatment resistance. Targeting of these programs should be considered in future studies investigating therapeutic strategies in relapsed and refractory OS.

cancer biology↗

Mitochondrial priming in human germ cell tumors is dependent on MCL1 and BCL2L1

Germ cell tumors (GCTs) are highly sensitized to cell death in response to DNA damaging agents, a property that underlies the success of current chemotherapeutic regimens. To address the molecular basis for this, known as apoptotic priming, we evaluated how different BCL2 family members modulate the heightened sensitivity of GCTs to therapy. Our analysis of human GCTs finds consistently high expression of the pro-survival factors MCL1 and BCL2L1 (BCLX) in a cohort of primary tumors and in their embryonic precursor cells, frequently accompanied by copy number gains of these loci and reciprocal losses of their pro-apoptotic interaction partners and inhibitors, PMAIP1 (NOXA) and BAD. We find that co-inhibition of MCL1 and BCLX using selective BH3 mimetics results in a potent synthetic lethality in multiple GCT embryonal carcinoma cell lines. When these cell lines were cultured with the DNA damaging agents cisplatin or etoposide, inhibition of MCL1 or BCLX potentiated their apoptotic effect in undifferentiated embryonal carcinoma cell lines, but not in retinoic acid-differentiated cells. The inhibition of MCL1 also heightened cisplatin sensitivity in p53-deficient or -mutant cell lines, which is associated with resistance to therapy. Employing an in ovo human xenograft model, we validate that the combination of cisplatin and MCL1 inhibition enhanced the therapeutic response by eliminating tumor cells. Our findings identify MCL1 and BCLX as critical factors to maintain GCT viability and as putative therapeutic targets to further augment GCT responsiveness to DNA damaging agents.

cancer biology↗

β3-Integrin controls pericyte metabolic states and shapes tumour-stromal metabolic crosstalk in breast cancer

Pericytes are emerging as dynamic regulators of the tumour microenvironment. Yet, their role in tumour metabolism remains elusive. Here, we investigate whether {beta}3-integrin regulates pericyte metabolic state and shapes stromal-tumour metabolic interactions in breast cancer. By integrating spatial and single-cell transcriptomics from human breast tumours with multi-omics profiling of tumour-derived pericytes in vitro, we identify two {beta}3-integrin-dependent metabolic states. {beta}3-integrin-high pericytes display a metabolically active phenotype characterised by increased glycolysis and enhanced de novo serine/glycine synthesis, supporting collagen production. In contrast, {beta}3-integrin loss induces a lipid-associated state, marked by neutral lipid accumulation and lipid droplets. Mechanistically, {beta}3-integrin regulates this metabolic switch via mTOR signalling. Importantly, these states extend beyond pericytes, with adjacent cancer cells shifting towards fatty acid oxidation and lipid use near {beta}3-integrin-low pericytes. Together, our findings establish {beta}3-integrin as a key metabolic switch in pericytes and highlight their role in driving tumour metabolic plasticity.

cancer biology↗